Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supported by all regions and segme ...

Group 1 - Fagron has obtained regulatory clearance for the acquisition of Vepakum in Brazil and has completed the acquisition of Magilab in Hungary [1][9] - The acquisition of Vepakum will enable Fagron to enter a new vertical in high-quality packaging solutions, providing scale benefits through joint packaging, distribution, and shared services [2] - The acquisition of Magilab strengthens Fagron's position in Hungary's hospital pharmacy segment, which has a high compounding per capita, and supports operational leverage through integration and scale [3] Group 2 - Fagron is a leading global company in pharmaceutical compounding, focusing on personalized medicine delivery to hospitals, pharmacies, clinics, and patients in over 35 countries [5] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [6]

Core Insights - Fagron has completed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder in California, enhancing its position in the health and wellness segment [1][2] - The acquisition is valued at approximately $41.5 million, with UCP generating annual revenues of around $25 million and an EBITDA margin lower than Fagron's existing group margin [3] - Fagron aims to realize synergies from the integration of UCP over the next 18 to 24 months, as part of its strategy to build a nationwide platform in the United States [3][4] Company Strategy - The acquisition of UCP complements Fagron's existing operations, particularly with Anazao, and strengthens its footprint in California, a highly regulated healthcare market [2][4] - Fagron has executed fourteen acquisitions across various regions recently, indicating a strategy of selective expansion and vertical integration [3][5] - The company remains focused on execution and integration of acquired businesses to build a larger, higher-quality compounding platform [5] Financial Outlook - Fagron's financial calendar includes key dates for full-year results, trading updates, and the annual general meeting, with the next full-year results scheduled for February 12, 2026 [5]

Core Insights - Fagron is expanding its global presence through two strategic acquisitions: Amber Compounding Pharmacy in Singapore and Malaysia, and Vepakum in Brazil, enhancing its capabilities in the pharmaceutical compounding market [1][2] - The acquisitions are expected to generate approximately €26 million in annual revenue with an EBITDA margin exceeding the current group margin, at a total purchase price of around €55 million, resulting in an average EV to EBITDA multiple of about 8x [3] - Fagron has also secured a license for its Anazao Health facility in Tampa, allowing the shipment of compounded medications to California, which strengthens its position in the U.S. healthcare market [4][7] Acquisition Details - Amber Compounding Pharmacy operates five strategic locations in Singapore and Malaysia, recognized as a leader in the compounding market, serving clinics, hospital pharmacies, and distributors [5] - Vepakum, based in São Paulo, Brazil, provides high-quality packaging solutions, enabling Fagron to achieve scale benefits through joint packaging and distribution [6] Licensing and Operational Updates - The license obtained for the Tampa facility allows for the shipment of compounded medications on a prescription basis, marking a significant milestone in Fagron's nationwide platform for Health and Wellness services [7][8] - Following the licensing, all Fagron facilities in the U.S. can now ship compounded medications to California, significantly enhancing operational flexibility [9]

Core Insights - Fagron has strengthened its leadership in the EMEA region through acquisitions in Poland and Hungary, aligning with its strategy to diversify in dynamic markets and emphasizing its disciplined M&A approach for sustainable growth [1][2][8] Acquisitions - The acquisitions of Amara in Poland and Magilab in Hungary are expected to contribute mid-teens (€m) in annual revenue with an EBITDA margin exceeding Fagron's existing group margin, with a combined purchase price of approximately €26 million [2][4][5] - Amara brings over 30 years of experience in the Polish compounding sector and enhances Fagron's offerings while unlocking significant synergy potential [4] - Magilab is a trusted brand in Hungary's hospital pharmacy segment, consolidating Fagron's position in a market characterized by high compounding per capita [5] Financial Developments - Fagron has secured a new U.S. dollar credit facility totaling up to $225 million with maturities extending up to 15 years, enhancing financial flexibility and supporting growth ambitions in North America [6] - An initial $125 million has been drawn from this facility, which complements an existing €575 million bank facility [6] Licensing and Market Presence - Fagron has received a license for its Fagron Sterile Services facility in Boston, allowing the shipment of compounding medication to California, a significant step in reinforcing its presence in a major U.S. healthcare market [3][7] - This license enables all of Fagron's 503B facilities in the U.S. to ship to California, unlocking further opportunities with key customers [7] Strategic Vision - The CEO of Fagron highlighted that the acquisitions and financial developments are crucial for consolidating leadership in EMEA and supporting global ambitions in the B&E segment [8][9] - The company emphasizes its commitment to disciplined M&A, operational excellence, and prudent balance sheet management as key enablers of sustained growth and long-term success [10]

Group 1 - Fagron completed a share buy-back program, repurchasing a total of 200,000 shares at an average price of €20.6805, amounting to €4,136,093 [1][2] - The recent buy-back occurred from 10 November 2025 to 14 November 2025, during which 44,000 shares were bought at an average price of €20.7208, totaling €911,717 [1] - The buy-back program was announced on 9 October 2025, and the repurchased shares will be used to meet obligations under Fagron's long-term incentive scheme [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 35 countries [4] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - Operational activities are managed through Fagron BV, which is headquartered in Rotterdam [5] Group 3 - The financial calendar includes key dates such as the full year results for 2025 on 12 February 2026 and the trading update for the first quarter of 2026 on 9 April 2026 [3]

Group 1 - Fagron has initiated a share buy-back program, purchasing 20,000 shares at an average price of €20.609, totaling €412,180 from 16 October 2025 to 17 October 2025 [1] - The share buy-back program aims to fulfill obligations under Fagron's long-term incentive scheme, with a total of up to 200,000 shares planned for repurchase [1] - To date, Fagron has purchased a total of 20,000 shares under this program [1] Group 2 - Fagron is a global leader in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Belgium and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam, Netherlands [4]

Core Insights - Fagron reported a solid third-quarter performance with a revenue growth of 6.4%, reaching €228.2 million, and confirmed its full-year revenue outlook of €930 – €950 million for 2025 [1][6][7] Group 1: Financial Performance - The company achieved an organic growth rate of 8.5% at constant exchange rates (CER) on a normalized basis, and 5.7% when accounting for the impact of GLP-1 drug shortages [7] - Revenue for Q3 2025 was €228.2 million, reflecting a 6.4% increase and a 10.3% increase at CER, driven by resilient structural drivers and focused commercial execution [7] Group 2: Regional Performance - EMEA showed broad-based progress across Brands, Essentials, and Compounding Services, with a mix of mature and growth markets responding positively to commercial efforts [3] - Latin America, particularly Brazil, continued strong momentum with targeted commercial activities and product launches supporting increased adoption [4] - North America remains a key growth engine, with planned capacity expansion and successful FDA inspections validating corrective actions [4] Group 3: M&A Activity - The company maintained momentum in mergers and acquisitions (M&A), signing University Compounding Pharmacy to strengthen its health and wellness platform in the U.S. [5] - Antitrust clearance for Purifarma and Injeplast in Brazil marks a significant milestone for expanding Fagron's portfolio and capabilities [5] - A total of eight acquisitions have been announced year-to-date, indicating ongoing strategic growth initiatives [7]

Core Viewpoint - Fagron has received Brazilian antitrust clearance for the acquisitions of Purifarma and Injeplast, marking a significant advancement in its M&A strategy in Latin America [1][2]. Group 1: Acquisitions and Strategic Importance - The acquisitions of Purifarma and Injeplast will enhance Fagron's portfolio and capabilities in Brazil, aligning with the company's long-term growth objectives [2]. - Purifarma's large-scale operations in Essentials present substantial potential for profitability improvements within 18 months post-closing through product portfolio expansion and operational efficiencies [3]. - Injeplast will enhance Fagron's vertical integration by providing high-quality packaging solutions, thereby broadening the product portfolio and customer base in Latin America and other regions [4]. Group 2: Management Commentary - CEO Rafael Padilla emphasized that the approvals from CADE facilitate the closing of the acquisitions, reinforcing Fagron's leadership in Brazil and supporting its strategy of combining targeted M&A with operational excellence while maintaining financial discipline [5]. Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine across more than 35 countries [6]. - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [7].

Core Viewpoint - Fagron has announced the acquisition of University Compounding Pharmacy (UCP) in North America, which will enhance its presence in the pharmaceutical compounding market, particularly in the health and wellness segment [1][3][4]. Group 1: Acquisition Details - The enterprise value of the acquisition is approximately $41.5 million, fully financed through Fagron's own resources, and is subject to customary clearance [5]. - UCP specializes in hormones and urology, and has a strong compliance record, making it a complementary addition to Fagron's existing operations [3][4]. - The acquisition is expected to generate around $25 million in annual revenue, with an EBITDA margin below Fagron's existing group margin, and synergies are anticipated over the next 18–24 months [5]. Group 2: FDA Inspection Update - Fagron's facilities in Wichita and Las Vegas were inspected by the FDA, with no repeated observations from the 2024 inspection in Wichita, indicating successful remediation of prior concerns [2][6]. - Following a new routine inspection, the FDA issued a Form 483 with six observations for Fagron Sterile Services and four observations for the 503B Anazao Health facility in Las Vegas [7]. - The company is committed to addressing the FDA's inspectional observations and is implementing corrective actions to enhance its protocols [8].